JP7387429B2 - 生細胞および生物の増殖および活性を制御するためのポリマー性金属キレート組成物およびその調製方法 - Google Patents

生細胞および生物の増殖および活性を制御するためのポリマー性金属キレート組成物およびその調製方法 Download PDF

Info

Publication number
JP7387429B2
JP7387429B2 JP2019511638A JP2019511638A JP7387429B2 JP 7387429 B2 JP7387429 B2 JP 7387429B2 JP 2019511638 A JP2019511638 A JP 2019511638A JP 2019511638 A JP2019511638 A JP 2019511638A JP 7387429 B2 JP7387429 B2 JP 7387429B2
Authority
JP
Japan
Prior art keywords
chelate
mahmp
chelate composition
group
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526671A (ja
JP2019526671A5 (https=
Inventor
イー． ホルベイン、ブルース
トリーシャ シー． エイエヌジー、エム．
ビトーバー パラスカー、ドニャネシュワール
サティヤナラヤナ、ガヌガパティ
マヘンドル、ジリーッシュ
ヴィジャヤ バースカラ レッディー、エス
アリ、サジド
Original Assignee
キレーション パートナーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キレーション パートナーズ インコーポレイテッド filed Critical キレーション パートナーズ インコーポレイテッド
Publication of JP2019526671A publication Critical patent/JP2019526671A/ja
Publication of JP2019526671A5 publication Critical patent/JP2019526671A5/ja
Application granted granted Critical
Publication of JP7387429B2 publication Critical patent/JP7387429B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/60—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing nitrogen in addition to the carbonamido nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/06—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
    • C08F226/10—N-Vinyl-pyrrolidone
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2438/00—Living radical polymerisation
    • C08F2438/03—Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymerisation Methods In General (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Materials For Medical Uses (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019511638A 2016-08-26 2017-08-25 生細胞および生物の増殖および活性を制御するためのポリマー性金属キレート組成物およびその調製方法 Active JP7387429B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380047P 2016-08-26 2016-08-26
US62/380,047 2016-08-26
PCT/CA2017/050999 WO2018035613A1 (en) 2016-08-26 2017-08-25 Polymeric metal chelating compositions and methods of preparing same for controlling growth and activities of living cells and organisms

Publications (3)

Publication Number Publication Date
JP2019526671A JP2019526671A (ja) 2019-09-19
JP2019526671A5 JP2019526671A5 (https=) 2020-10-08
JP7387429B2 true JP7387429B2 (ja) 2023-11-28

Family

ID=61245905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019511638A Active JP7387429B2 (ja) 2016-08-26 2017-08-25 生細胞および生物の増殖および活性を制御するためのポリマー性金属キレート組成物およびその調製方法

Country Status (6)

Country Link
US (2) US11059785B2 (https=)
EP (1) EP3504188A4 (https=)
JP (1) JP7387429B2 (https=)
AU (2) AU2017314880B2 (https=)
CA (1) CA3034540A1 (https=)
WO (1) WO2018035613A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7387429B2 (ja) * 2016-08-26 2023-11-28 キレーション パートナーズ インコーポレイテッド 生細胞および生物の増殖および活性を制御するためのポリマー性金属キレート組成物およびその調製方法
CN108276303A (zh) * 2018-03-14 2018-07-13 中国科学院青岛生物能源与过程研究所 一种含糖聚合物单体n-(2-d-葡萄糖酰胺基乙基)甲基丙烯酰胺的合成方法
US20220390470A1 (en) * 2019-11-11 2022-12-08 Oxford University Innovation Limited Biomarkers for the prediction and identification of parkinson's disease
CN111995567B (zh) * 2020-07-24 2022-11-25 浙江工业大学 具潜在多靶点抗ad活性的甲酰胺吡啶酮类铁螯合剂衍生物及其制备方法与应用
JP2025510226A (ja) * 2022-03-24 2025-04-14 フィー ファーマシューティカルズ（カナダ）インコーポレイテッド ポリマー鉄結合組成物及び過剰な損傷反応性鉄に関連する疾患を治療するための使用方法
EP4619007A1 (en) * 2022-11-18 2025-09-24 Fe Pharmaceuticals (Canada) Inc. Compositions for attenuating anti-infective resistance, uses and methods thereof
CA3226246A1 (en) * 2023-02-17 2025-05-02 Infineum International Limited Multipurpose oxypyridinones and their functional use
CN118955773B (zh) * 2024-07-31 2025-09-26 浙江大学 高聚合度的金属螯合聚合物抗体标签载体材料的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070274945A1 (en) 2006-05-25 2007-11-29 Scott Mark D High molecular weight chelation structure
JP2011522070A (ja) 2008-05-13 2011-07-28 ユニヴァーシティ オブ ワシントン ミセル集合体
JP2014522405A (ja) 2011-06-08 2014-09-04 キレーション パートナーズ インコーポレイテッド 生きている細胞または生物体の増殖または活性を制御するための金属キレート組成物および方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7387429B2 (ja) * 2016-08-26 2023-11-28 キレーション パートナーズ インコーポレイテッド 生細胞および生物の増殖および活性を制御するためのポリマー性金属キレート組成物およびその調製方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070274945A1 (en) 2006-05-25 2007-11-29 Scott Mark D High molecular weight chelation structure
JP2011522070A (ja) 2008-05-13 2011-07-28 ユニヴァーシティ オブ ワシントン ミセル集合体
JP2014522405A (ja) 2011-06-08 2014-09-04 キレーション パートナーズ インコーポレイテッド 生きている細胞または生物体の増殖または活性を制御するための金属キレート組成物および方法

Also Published As

Publication number Publication date
WO2018035613A1 (en) 2018-03-01
US20220002250A1 (en) 2022-01-06
AU2017314880B2 (en) 2021-07-29
AU2021204603A1 (en) 2021-07-29
EP3504188A4 (en) 2020-04-22
EP3504188A1 (en) 2019-07-03
US12024490B2 (en) 2024-07-02
CA3034540A1 (en) 2018-03-01
JP2019526671A (ja) 2019-09-19
AU2017314880A1 (en) 2019-04-11
AU2021204603B2 (en) 2023-02-23
US20190169126A1 (en) 2019-06-06
US11059785B2 (en) 2021-07-13

Similar Documents

Publication Publication Date Title
JP7387429B2 (ja) 生細胞および生物の増殖および活性を制御するためのポリマー性金属キレート組成物およびその調製方法
Das et al. Dextrin cross linked with poly (HEMA): a novel hydrogel for colon specific delivery of ornidazole
Kumar et al. Synthesis of xanthan gum graft copolymer and its application for controlled release of highly water soluble Levofloxacin drug in aqueous medium
CN102770407A (zh) 交联的两性离子水凝胶
Bielas et al. Choline supported poly (ionic liquid) graft copolymers as novel delivery systems of anionic pharmaceuticals for anti-inflammatory and anti-coagulant therapy
Giaouzi et al. PNIPAM-b-PDMAEA double stimuli responsive copolymers: Effects of composition, end groups and chemical modification on solution self-assembly
Mrlik et al. Mussel-mimicking sulfobetaine-based copolymer with metal tunable gelation, self-healing and antibacterial capability
Mei et al. Multivalent polymer–Au nanocomposites with cationic surfaces displaying enhanced antimicrobial activity
García et al. A novel gel based on an ionic complex from a dendronized polymer and ciprofloxacin: Evaluation of its use for controlled topical drug release
Ghosh et al. Antibacterial activity of hydrophobicity modulated cationic polymers with enzyme and pH-responsiveness
Sehlinger et al. Potentially biocompatible polyacrylamides derived by the Ugi four-component reaction
Sun et al. Facile synthesis of multiamino vinyl poly (amino acid) s for promising bioapplications
Liu et al. A one-pot synthesis of oleic acid end-capped temperature-and pH-sensitive amphiphilic polymers
Biswas et al. A bioinspired stimuli-responsive amino acid-based antibacterial drug delivery system in cancer therapy
Datta et al. RAFT derived fatty acid based stimuli responsive fluorescent block copolymers as DNA sensor and cargo delivery agent
Bărăian et al. Targeting JAK/STAT3 in glioblastoma cells using an alginate-PNIPAm molecularly imprinted hydrogel for the sustained release of ruxolitinib
CA3082835A1 (fr) Prodrogues polymeres et leur administration sous-cutanee et/ou intramusculaire
JP2019142813A (ja) 細胞増殖抑制用医薬組成物
US12257312B2 (en) Conjugates comprising a temperature-responsive polymer and a ligand capable of binding ergosterol
CN109705262B (zh) 一种阳离子抗菌聚合物及其制备方法和应用
Li et al. Macromolecular iron-chelators via RAFT-polymerization for the inhibition of methicillin-resistant Staphylococcus aureus growth
CN104844746B (zh) 一种具有多重刺激响应性的水溶性聚合物及其制备方法
Göktaş et al. Synthesis and characterization of a brush type graft copolymer via RAFT and" click" chemistry methods
Mahmood et al. New n-substituted itaconimide polymers: Synthesis, characterization, and biological activity
Strelova et al. Copolymers of methyl acrylate and vinylazoles: synthesis, thermolabile properties, and grafting of polyamine chains

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200820

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231115

R150 Certificate of patent or registration of utility model

Ref document number: 7387429

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150